[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 24 of about 24
1. Simon D, Schoenrock D, Baumgärtner W, Nolte I: Postoperative adjuvant treatment of invasive malignant mammary gland tumors in dogs with doxorubicin and docetaxel. J Vet Intern Med; 2006 Sep-Oct;20(5):1184-90
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative adjuvant treatment of invasive malignant mammary gland tumors in dogs with doxorubicin and docetaxel.
  • BACKGROUND: Treatment outcome after surgery alone is unsatisfactory in dogs with invasive malignant mammary gland tumors.
  • HYPOTHESIS: Adjuvant doxorubicin or docetaxel will improve the treatment outcome in dogs with high-risk malignant mammary gland tumors, and the use of docetaxel will be feasible in affected dogs.
  • ANIMALS: Thirty-one dogs with malignant mammary gland tumors of histologic stages II and III (vascular or lymphatic invasion, regional lymph node metastasis, or distant metastasis) were used.
  • METHODS: A prospective clinical trial in which dogs were treated with surgery alone (n = 19) or also received adjuvant chemotherapy (n = 12) with doxorubicin or docetaxel was conducted.
  • Dogs treated with chemotherapy had a tendency toward higher long-term local control and survival rates, but there was no significant difference in the recurrence-free interval (P = .17), time to metastasis (P = .71), and overall survival (P = .12).
  • Factors found to influence the time to metastasis and overall survival included lymph node metastasis (P = .009) and tumor fixation to underlying structures (P = .043, time to metastasis), as well as age (P = .018) and histologic stage (P < .001, survival).
  • Mild allergic skin reactions were the most frequently observed complications of docetaxel treatment.
  • CONCLUSIONS AND CLINICAL IMPORTANCE: Chemotherapy did not lead to an improved outcome in this population.
  • Docetaxel treatment was well tolerated.
  • Additional investigations of adjuvant chemotherapy in dogs with high-risk mammary cancer are warranted.

  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17063714.001).
  • [ISSN] 0891-6640
  • [Journal-full-title] Journal of veterinary internal medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] ENG
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; 80168379AG / Doxorubicin
  •  go-up   go-down


2. Asavamongkolkul A, Pimolsanti R, Waikakul S, Kiatsevee P: Periacetabular limb salvage for malignant bone tumours. J Orthop Surg (Hong Kong); 2005 Dec;13(3):273-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Periacetabular limb salvage for malignant bone tumours.
  • PURPOSE: To evaluate treatment outcomes in primary malignant periacetabular bone tumour removal and limb salvage with or without bone-graft reconstruction.
  • METHODS: A total of 13 patients were treated for malignant periacetabular bone tumours at Siriraj Hospital, Bangkok, Thailand.
  • The diagnoses were chondrosarcoma (n=8), Ewing's sarcoma (n=2), osteosarcoma (n=1), well-differentiated osteosarcoma (n=1), and malignant giant cell tumour (n=1).
  • 11 patients did not undergo reconstruction following tumour resection; 2 patients received fibular bone grafts bridging the periacetabulum to the remaining sacrum.
  • Adjuvant chemotherapy was administered for high-grade malignant tumours, and postoperative radiation therapy was performed on patients with a closed surgical margin.
  • According to the Musculoskeletal Tumor Society classification system, the mean functional analysis at final follow-up was 68.7%.
  • Four patients had complications (one each for deep wound infection, skin necrosis, seroma, and vascular spasms) and were successfully treated with multiple debridements and appropriate antibiotics.
  • CONCLUSION: Malignant periacetabular tumours are difficult to manage.
  • [MeSH-major] Bone Neoplasms / therapy. Limb Salvage. Pelvic Bones
  • [MeSH-minor] Adult. Bone Transplantation. Chemotherapy, Adjuvant. Child. Chondrosarcoma / therapy. Combined Modality Therapy. Disease-Free Survival. Female. Giant Cell Tumor of Bone / therapy. Humans. Male. Middle Aged. Osteosarcoma / therapy. Sarcoma, Ewing / therapy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16365491.001).
  • [ISSN] 1022-5536
  • [Journal-full-title] Journal of orthopaedic surgery (Hong Kong)
  • [ISO-abbreviation] J Orthop Surg (Hong Kong)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


3. Casanova ML, Blázquez C, Martínez-Palacio J, Villanueva C, Fernández-Aceñero MJ, Huffman JW, Jorcano JL, Guzmán M: Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest; 2003 Jan;111(1):43-50
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors.
  • Nonmelanoma skin cancer is one of the most common malignancies in humans.
  • Different therapeutic strategies for the treatment of these tumors are currently being investigated.
  • Given the growth-inhibiting effects of cannabinoids on gliomas and the wide tissue distribution of the two subtypes of cannabinoid receptors (CB(1) and CB(2)), we studied the potential utility of these compounds in anti-skin tumor therapy.
  • Here we show that the CB(1) and the CB(2) receptor are expressed in normal skin and skin tumors of mice and humans.
  • In cell culture experiments pharmacological activation of cannabinoid receptors induced the apoptotic death of tumorigenic epidermal cells, whereas the viability of nontransformed epidermal cells remained unaffected.
  • Local administration of the mixed CB(1)/CB(2) agonist WIN-55,212-2 or the selective CB(2) agonist JWH-133 induced a considerable growth inhibition of malignant tumors generated by inoculation of epidermal tumor cells into nude mice.
  • This was accompanied by impairment of tumor vascularization, as determined by altered blood vessel morphology and decreased expression of proangiogenic factors (VEGF, placental growth factor, and angiopoietin 2).
  • These results support a new therapeutic approach for the treatment of skin tumors.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BROMODEOXYURIDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1996 Dec 1;56(23):5391-6 [8968091.001]
  • [Cites] EMBO J. 1995 Nov 1;14(21):5216-23 [7489711.001]
  • [Cites] Carcinogenesis. 1998 Dec;19(12):2107-13 [9886564.001]
  • [Cites] Med Clin North Am. 1998 Nov;82(6):1309-23, vi [9889750.001]
  • [Cites] Nature. 1998 Jul 16;394(6690):277-81 [9685157.001]
  • [Cites] Nature. 1990 Aug 9;346(6284):561-4 [2165569.001]
  • [Cites] J Cell Biol. 1990 Dec;111(6 Pt 2):2807-14 [2269655.001]
  • [Cites] Science. 1992 Dec 18;258(5090):1946-9 [1470919.001]
  • [Cites] Cell. 1993 Apr 23;73(2):263-78 [8477445.001]
  • [Cites] Nature. 1993 Sep 2;365(6441):61-5 [7689702.001]
  • [Cites] Genes Dev. 1994 Feb 15;8(4):399-413 [8125255.001]
  • [Cites] Mol Carcinog. 1994 Sep;11(1):19-28 [7916986.001]
  • [Cites] J Natl Cancer Inst. 1995 Feb 1;87(3):213-9 [7535859.001]
  • [Cites] Biochem Pharmacol. 1995 Jun 29;50(1):83-90 [7605349.001]
  • [Cites] Nurse Pract Forum. 1999 Jun;10(2):106-12 [10542587.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Dec 7;96(25):14228-33 [10588688.001]
  • [Cites] Bioorg Med Chem. 1999 Dec;7(12):2905-14 [10658595.001]
  • [Cites] Cancer Res. 2000 Jan 15;60(2):226-9 [10667563.001]
  • [Cites] Nat Med. 2000 Mar;6(3):313-9 [10700234.001]
  • [Cites] Trends Pharmacol Sci. 2000 Jun;21(6):218-24 [10838609.001]
  • [Cites] Cell. 2000 Jul 21;102(2):211-20 [10943841.001]
  • [Cites] Nature. 2000 Sep 14;407(6801):242-8 [11001067.001]
  • [Cites] Nature. 2000 Sep 14;407(6801):249-57 [11001068.001]
  • [Cites] FASEB J. 2000 Nov;14(14):2315-22 [11053253.001]
  • [Cites] Eur J Dermatol. 2000 Oct-Nov;10(7):505-10 [11056418.001]
  • [Cites] Expert Opin Investig Drugs. 2000 Jul;9(7):1553-71 [11060760.001]
  • [Cites] Tex Med. 2001 Feb;97(2):56-8 [11233060.001]
  • [Cites] J Mol Med (Berl). 2001;78(11):613-25 [11269508.001]
  • [Cites] Pharm Res. 2000 Dec;17(12):1447-55 [11303952.001]
  • [Cites] EMBO J. 2001 Jun 1;20(11):2631-40 [11387198.001]
  • [Cites] Pharmacol Ther. 2001 Apr;90(1):45-60 [11448725.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5784-9 [11479216.001]
  • [Cites] Pain. 2001 Sep;93(3):239-45 [11514083.001]
  • [Cites] FASEB J. 2001 Dec;15(14):2745-7 [11687506.001]
  • [Cites] Nature. 2002 Mar 21;416(6878):279-80 [11907566.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3402-7 [12067982.001]
  • [Cites] J Natl Cancer Inst. 1975 Sep;55(3):597-602 [1159836.001]
  • [Cites] Jpn J Cancer Res. 1985 Aug;76(8):663-6 [2995289.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Cancer Res. 1995 Oct 15;55(20):4575-80 [7553632.001]
  • [Cites] J Biol Chem. 1995 Oct 27;270(43):25915-9 [7592779.001]
  • [Cites] Oncogene. 1998 Jul 23;17(3):303-11 [9690512.001]
  • (PMID = 12511587.001).
  • [ISSN] 0021-9738
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] ENG
  • [Grant] United States / NIDA NIH HHS / DA / R01 DA003590; United States / NIDA NIH HHS / DA / DA03590
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 1,1-dimethylbutyl-1-deoxy-Delta(9)-THC; 0 / Angiogenesis Inducing Agents; 0 / Angiopoietin-2; 0 / Antineoplastic Agents; 0 / Benzoxazines; 0 / Cannabinoids; 0 / Endothelial Growth Factors; 0 / Intercellular Signaling Peptides and Proteins; 0 / Lymphokines; 0 / Morpholines; 0 / Naphthalenes; 0 / Receptors, Cannabinoid; 0 / Receptors, Drug; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factors; 134959-51-6 / Win 55212-2; G34N38R2N1 / Bromodeoxyuridine
  • [Other-IDs] NLM/ PMC151833
  •  go-up   go-down


Advertisement
4. Al Dhaybi R, Agoumi M, Powell J, Dubois J, Kokta V: Lymphangiosarcoma complicating extensive congenital mixed vascular malformations. Lymphat Res Biol; 2010 Sep;8(3):175-9
Genetic Alliance. consumer health - Vascular Malformations.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphangiosarcoma complicating extensive congenital mixed vascular malformations.
  • Pediatric hepatic angiosarcoma is a very rare malignant vascular tumor.
  • A few cases have shown pediatric hepatic angiosarcoma occurring on a background of preexisting vascular lesions.
  • We report the case of a newborn girl who presented extensive limbs and upper trunk cutaneous mixed vascular malformations at birth.
  • Cutaneous biopsies revealed complex vascular malformations with a significant lymphatic component.
  • Compressive body suit therapy led to regression of the limbs' cutaneous vascular malformations.
  • Aggressive treatment with prednisone, vincristine, and hepatosplenic embolizations resulted in initial improvement of the hepatosplenic lesions for few months, followed by an increase of the lesions with failure of response to treatment despite adding alpha-interferon-2b to treatment.
  • Multiple cutaneous and visceral complex capillaro-lymphatico-venous malformations were also identified.
  • We hypothesize that these multiple extensive mixed vascular malformations were associated with chronic lymphedema which probably predisposed to the development of the angiosarcoma in our patient.
  • [MeSH-major] Lymphangiosarcoma / complications. Vascular Malformations / complications
  • [MeSH-minor] Autopsy. Fatal Outcome. Female. Humans. Infant. Infant, Newborn. Skin Diseases, Vascular / complications. Skin Diseases, Vascular / congenital. Skin Diseases, Vascular / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20863270.001).
  • [ISSN] 1557-8585
  • [Journal-full-title] Lymphatic research and biology
  • [ISO-abbreviation] Lymphat Res Biol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Ishii A, Nishiguchi T, Kitagawa T, Yagi M, Hakamada A, Isoda K, Kurokawa I, Hara K, Mizutani H: A case of epidermotropic metastatic malignant melanoma with multiple nodular lesions of the scalp. J Dermatol; 2005 Oct;32(10):821-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of epidermotropic metastatic malignant melanoma with multiple nodular lesions of the scalp.
  • Epidermotropic metastatic malignant melanoma (EMMM) is a form of metastatic malignant melanoma that has dermal cell nests with epidermotropism and specific histopathological features.
  • The tumors developed one year before consultation and increased in size simultaneously.
  • The tumor cells were located mainly in the dermis and partly in the basal layer of the epidermis.
  • The tumors did not respond to combination chemotherapy with dacarbazine, nimustine, vincristine, and interferon-beta.
  • Histopathologically, all eight tumors lacked apparent vascular invasion, which may be related to a slow clinical course of the present case.
  • [MeSH-major] Head and Neck Neoplasms / pathology. Melanoma / pathology. Melanoma / secondary. Scalp. Skin Neoplasms / pathology


6. Corsini E, Gelati M, Calatozzolo C, Alessandri G, Frigerio S, De Francesco M, Poiesi C, Parati E, Croci D, Boiardi A, Salmaggi A: Immunotherapy with bovine aortic endothelial cells in subcutaneous and intracerebral glioma models in rats: effects on survival time, tumor growth, and tumor neovascularization. Cancer Immunol Immunother; 2004 Nov;53(11):955-62
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunotherapy with bovine aortic endothelial cells in subcutaneous and intracerebral glioma models in rats: effects on survival time, tumor growth, and tumor neovascularization.
  • Conventional antitumoral treatments (i.e., surgery, radiotherapy, and chemotherapy) do not achieve satisfactory results (median survival in glioblastoma 12-18 months).
  • It has been suggested that immunotherapy with xenogenic endothelial cells could slow tumor growth rate in a number of tumors in a murine model, but the study did not include gliomas.
  • In experiments performed in our laboratory, vaccination with proliferating bovine aortic endothelium increased survival time in Fischer rats inoculated intracerebrally with 9L.
  • Moreover, immune sera from immunized rats stained microvessels of human malignant glioma specimens and vessels of intracerebrally implanted tumors.
  • [MeSH-major] Aorta / cytology. Brain Neoplasms / therapy. Endothelial Cells / cytology. Endothelium, Vascular / cytology. Glioma / therapy. Immunotherapy / methods. Skin Neoplasms / therapy
  • [MeSH-minor] Animals. Blotting, Western. Brain / metabolism. Cattle. Cell Division. Cell Line, Tumor. Cells, Cultured. Humans. Immunoglobulin G / blood. Immunoglobulin G / chemistry. Immunoglobulins / chemistry. Injections, Subcutaneous. Interferon-gamma / metabolism. Microcirculation. Neoplasms / pathology. Neovascularization, Pathologic. Rats. Rats, Inbred F344. Time Factors. Tumor Necrosis Factor-alpha / metabolism

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15449042.001).
  • [ISSN] 0340-7004
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Immunoglobulin G; 0 / Immunoglobulins; 0 / Tumor Necrosis Factor-alpha; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


7. Kondraganti S, Gondi CS, Gujrati M, McCutcheon I, Dinh DH, Rao JS, Olivero WC: Restoration of tissue factor pathway inhibitor inhibits invasion and tumor growth in vitro and in vivo in a malignant meningioma cell line. Int J Oncol; 2006 Jul;29(1):25-32
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Restoration of tissue factor pathway inhibitor inhibits invasion and tumor growth in vitro and in vivo in a malignant meningioma cell line.
  • Tissue factor pathway inhibitor 2 (TFPI-2) is a 32-kDa extracellular matrix-associated kunitz-type serine proteinase inhibitor.
  • It is secreted by all vascular cells and plays a role in tumor invasion and metastasis, presumably by plasmin-mediated matrix remodeling.
  • Previous studies have shown high expression of TFPI-2 by benign tumors and low or absent expression in highly malignant tumors.
  • Malignant meningiomas constitute 10-15% of all meningiomas and our previous studies revealed loss of expression of TFPI-2 in malignant gliomas.
  • To investigate the role of TFPI-2 in the invasiveness of malignant meningiomas, we stably transfected the human meningioma cell line, IOMM-Lee, with a vector capable of expressing a transcript complementary to the full length of TFPI-2 mRNA in a sense orientation.
  • Restoration of TFPI-2 led to decreased invasiveness of transfected cells compared to parental and vector controls in Matrigel and spheroid assays and inhibition of angiogenesis in in vitro co-cultures with human umbilical vein endothelial cells (HUVEC) and in vivo dorsal skin assay studies.
  • Finally, TFPI-2 overexpression inhibited intracranial tumor formation in nude mice.
  • Our data substantiate our previous observation that TFPI-2 plays an important role in tumor progression and has potential in anti-cancer therapy.

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Biochem Biophys. 1995 Feb 20;317(1):311-4 [7872799.001]
  • [Cites] Cancer Res. 1993 Sep 15;53(18):4143-7 [8395977.001]
  • [Cites] J Biochem. 1994 Nov;116(5):939-42 [7896752.001]
  • [Cites] Arch Biochem Biophys. 1995 May 10;319(1):55-62 [7539605.001]
  • [Cites] Eur J Biochem. 1996 Jan 15;235(1-2):310-6 [8631347.001]
  • [Cites] Cancer. 1996 May 1;77(9):1877-83 [8646688.001]
  • [Cites] Genomics. 1996 Jul 1;35(1):267-8 [8661135.001]
  • [Cites] Oncology (Williston Park). 1996 May;10(5):747-56; discussion 756-9 [8738830.001]
  • [Cites] Science. 1997 Feb 21;275(5303):1132-6 [9027315.001]
  • [Cites] Cell. 1997 Feb 7;88(3):355-65 [9039262.001]
  • [Cites] Clin Exp Metastasis. 1997 Jul;15(4):440-6 [9219733.001]
  • [Cites] Trends Biochem Sci. 1997 Aug;22(8):299-306 [9270303.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 1998 Jan;18(1):40-6 [9445254.001]
  • [Cites] Blood. 1998 Apr 15;91(8):2698-703 [9531578.001]
  • [Cites] Placenta. 1998 Mar-Apr;19(2-3):217-23 [9548189.001]
  • [Cites] Int J Cancer. 1998 May 29;76(5):749-56 [9610735.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9064-6 [9689032.001]
  • [Cites] Semin Thromb Hemost. 1998;24(3):207-10 [9701449.001]
  • [Cites] Cancer Res. 1998 Oct 1;58(19):4461-7 [9766679.001]
  • [Cites] Oncogene. 1998 Dec 24;17(25):3247-59 [9916987.001]
  • [Cites] Cell Death Differ. 1999 Jul;6(7):673-82 [10453078.001]
  • [Cites] Arch Biochem Biophys. 1999 Oct 1;370(1):112-8 [10496984.001]
  • [Cites] J Neurosurg. 1995 Jan;82(1):17-27 [7815129.001]
  • [Cites] J Invest Dermatol. 1995 Mar;104(3):379-83 [7861006.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3353-7 [8159751.001]
  • [Cites] Int J Oncol. 2001 Jan;18(1):127-31 [11115549.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3):570-6 [11297250.001]
  • [Cites] J Biol Chem. 2001 Apr 13;276(15):12241-8 [11278667.001]
  • [Cites] Clin Exp Metastasis. 2000;18(3):239-44 [11315097.001]
  • [Cites] Int J Oncol. 2001 Sep;19(3):591-7 [11494041.001]
  • [Cites] Gynecol Oncol. 2001 Nov;83(2):325-33 [11606093.001]
  • [Cites] Oncogene. 2001 Oct 18;20(47):6938-45 [11687973.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):2184-91 [11929842.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350-4 [388439.001]
  • [Cites] Cancer Res. 1990 Dec 15;50(24):7758-64 [2253219.001]
  • [Cites] J Biochem. 1990 Oct;108(4):537-43 [1963430.001]
  • [Cites] Cancer Res. 1992 Sep 15;52(18):5046-53 [1387587.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):11832-6 [1465406.001]
  • (PMID = 16773181.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS47699; United States / NCI NIH HHS / CA / R01 CA075557; United States / NCI NIH HHS / CA / CA75557; United States / NCI NIH HHS / CA / CA116708; United States / NCI NIH HHS / CA / CA95058; United States / NCI NIH HHS / CA / R01 CA116708; United States / NINDS NIH HHS / NS / R01 NS047699; United States / NCI NIH HHS / CA / R01 CA095058; United States / NCI NIH HHS / CA / R01 CA092393; United States / NCI NIH HHS / CA / CA92393
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Glycoproteins; 0 / Laminin; 0 / Lipoproteins; 0 / Proteoglycans; 0 / bcl-2-Associated X Protein; 0 / lipoprotein-associated coagulation inhibitor; 0 / tissue-factor-pathway inhibitor 2; 119978-18-6 / matrigel; 9007-34-5 / Collagen; 9007-43-6 / Cytochromes c; EC 3.4.22.- / Caspase 3
  • [Other-IDs] NLM/ NIHMS9141; NLM/ PMC1479607
  •  go-up   go-down


8. Gille J: Antiangiogenic cancer therapies get their act together: current developments and future prospects of growth factor- and growth factor receptor-targeted approaches. Exp Dermatol; 2006 Mar;15(3):175-86
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antiangiogenic cancer therapies get their act together: current developments and future prospects of growth factor- and growth factor receptor-targeted approaches.
  • Targeting the vascular endothelial growth factor (VEGF) in combination with standard chemotherapy has recently proved successful in the treatment of different types of advanced cancer.
  • The achievements of combinatorial anti-VEGF monoclonal antibody bevacizumab (BEV) renewed the confidence in targeted antiangiogenic approaches to constitute a complementary therapeutic modality in addition to surgery, radiotherapy and chemotherapy.
  • While several second-generation multitargeted tyrosine kinase inhibitors show promise in defined tumor entities, these novel antiangiogenic compounds have yet to meet or exceed the efficacy of combinatorial BEV therapy in ongoing clinical trials.
  • Current developments of targeted antiangiogenic agents include their use in the adjuvant setting and the combination of different antiangiogenesis inhibitors to take a more comprehensive approach in blocking tumor angiogenesis.
  • The identification of surrogate markers that can monitor the activity and efficacy of antiangiogenic drugs in patients belongs to the most critical challenges to exploit the full potential of antiangiogenic therapies.
  • The opportunities and obstacles in further development of growth factor- and growth factor receptor-targeted antiangiogenic approaches for advanced cancer, including malignant melanoma, will be discussed herein with particular reference to selected ongoing clinical trials.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Skin Neoplasms / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Bevacizumab. Colorectal Neoplasms / drug therapy. Combined Modality Therapy. Epidermal Growth Factor / antagonists & inhibitors. Humans. Platelet-Derived Growth Factor / antagonists & inhibitors. Receptor Protein-Tyrosine Kinases / antagonists & inhibitors. Vascular Endothelial Growth Factor A / antagonists & inhibitors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16480425.001).
  • [ISSN] 0906-6705
  • [Journal-full-title] Experimental dermatology
  • [ISO-abbreviation] Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Platelet-Derived Growth Factor; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab; 62229-50-9 / Epidermal Growth Factor; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases
  • [Number-of-references] 54
  •  go-up   go-down


9. Ferrario A, Gomer CJ: Targeting the tumor microenvironment using photodynamic therapy combined with inhibitors of cyclooxygenase-2 or vascular endothelial growth factor. Methods Mol Biol; 2010;635:121-32
Hazardous Substances Data Bank. CELECOXIB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting the tumor microenvironment using photodynamic therapy combined with inhibitors of cyclooxygenase-2 or vascular endothelial growth factor.
  • Photodynamic therapy (PDT) involves the administration of a photosensitizer (PS) followed by localized exposure of a targeted tissue to PS adsorbing light.
  • PDT induces cytotoxicity to exposed malignant cells and also effects non-malignant components of the tumor microenvironment.
  • This indirect action of PDT leads to inflammatory and proangiogenic responses and modulates treatment effectiveness.
  • Preclinical studies designed to determine how PDT modulates the tumor microenvironment use murine tumor models to investigate the expression and/or the activation of growth factors, proteinases, and inflammatory molecules following treatment.
  • These studies demonstrate that improvements in treatment responsiveness following PDT are achieved using inhibitors targeting angiogenic and/or inflammatory pathways.
  • [MeSH-major] Cyclooxygenase 2 / metabolism. Cyclooxygenase 2 Inhibitors / pharmacology. Neoplasms / drug therapy. Photochemotherapy. Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • [MeSH-minor] Animals. Celecoxib. Cell Line, Tumor. Cell Transformation, Neoplastic. Combined Modality Therapy. Dihematoporphyrin Ether / administration & dosage. Dihematoporphyrin Ether / pharmacology. Dihematoporphyrin Ether / therapeutic use. Dinoprostone / metabolism. Female. Humans. Injections. Light. Mice. Nitrobenzenes / pharmacology. Nitrobenzenes / therapeutic use. Pyrazoles / pharmacology. Pyrazoles / therapeutic use. Skin / drug effects. Skin / radiation effects. Sulfonamides / pharmacology. Sulfonamides / therapeutic use. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20552344.001).
  • [ISSN] 1940-6029
  • [Journal-full-title] Methods in molecular biology (Clifton, N.J.)
  • [ISO-abbreviation] Methods Mol. Biol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA031230
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclooxygenase 2 Inhibitors; 0 / Nitrobenzenes; 0 / Pyrazoles; 0 / Sulfonamides; 0 / Vascular Endothelial Growth Factor A; 123653-11-2 / N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide; 97067-70-4 / Dihematoporphyrin Ether; EC 1.14.99.1 / Cyclooxygenase 2; JCX84Q7J1L / Celecoxib; K7Q1JQR04M / Dinoprostone
  •  go-up   go-down


10. Vihinen PP, Hilli J, Vuoristo MS, Syrjänen KJ, Kähäri VM, Pyrhönen SO: Serum VEGF-C is associated with metastatic site in patients with malignant melanoma. Acta Oncol; 2007;46(5):678-84
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum VEGF-C is associated with metastatic site in patients with malignant melanoma.
  • Vascular endothelial growth factor-C (VEGF-C) is involved in lymphatic metastatic spread.
  • The study included 64 patients, who received dacarbazine or four-drug chemotherapy (dacarbazine, vincristine, bleomycin and lomustine;.
  • The patients (n =22) with only skin and subcutaneous metastases had significantly lower mean VEGF-C levels (1 643 pg/ml) then the patients (n =42) with other distant metastases (2 584 pg/ml, Mann-Whitney, p =0.033).
  • There were no other significant associations between VEGF-C levels and tumour burden, nor were the levels significantly related to the response to therapy or survival.
  • Those eight patients, who had received previous adjuvant IFN-alfa therapy had lower mean VEGF-C levels (1 738 pg/ml) as compared to those 56 patients without previous IFN-alfa therapy (2 335 pg/ml, ANOVA, p =0.026).
  • [MeSH-major] Biomarkers, Tumor / blood. Melanoma / secondary. Skin Neoplasms / pathology. Vascular Endothelial Growth Factor C / blood

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17562445.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Vascular Endothelial Growth Factor C
  •  go-up   go-down


11. Arbiser JL, Weiss SW, Arbiser ZK, Bravo F, Govindajaran B, Caceres-Rios H, Cotsonis G, Recavarren S, Swerlick RA, Cohen C: Differential expression of active mitogen-activated protein kinase in cutaneous endothelial neoplasms: implications for biologic behavior and response to therapy. J Am Acad Dermatol; 2001 Feb;44(2):193-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of active mitogen-activated protein kinase in cutaneous endothelial neoplasms: implications for biologic behavior and response to therapy.
  • BACKGROUND: Tumors of endothelium range from benign hemangiomas of infancy to highly malignant angiosarcomas of the elderly.
  • Activation of mitogen-activated protein kinase (MAPK) is an important signal transduction mechanism that may predict response of a tumor to chemotherapy.
  • METHODS: Skin sections from benign and malignant endothelial tumors, including hemangioma of infancy, angiosarcoma, and infectious endothelial lesions (Kaposi's sarcoma, verruga peruana) were stained with an antibody specific for phosphorylated MAPK.
  • CONCLUSION: We demonstrate that the use of antibodies specific for signal transduction pathways is feasible in paraffin-fixed tissue.
  • Immunohistochemistry for phosphorylated MAPK may help the pathologist distinguish benign from malignant endothelial processes and thus guide therapy.
  • [MeSH-major] Mitogen-Activated Protein Kinases / analysis. Neoplasms, Vascular Tissue / enzymology. Skin Neoplasms / enzymology
  • [MeSH-minor] Granuloma, Pyogenic / drug therapy. Granuloma, Pyogenic / enzymology. Granuloma, Pyogenic / pathology. Hemangioendothelioma / drug therapy. Hemangioendothelioma / enzymology. Hemangioendothelioma / pathology. Hemangioma / drug therapy. Hemangioma / enzymology. Hemangioma / pathology. Hemangiosarcoma / drug therapy. Hemangiosarcoma / enzymology. Hemangiosarcoma / pathology. Humans. Immunohistochemistry. Sarcoma, Kaposi / drug therapy. Sarcoma, Kaposi / enzymology. Sarcoma, Kaposi / pathology. Skin Diseases / drug therapy. Skin Diseases / enzymology. Skin Diseases / pathology. Warts / drug therapy. Warts / enzymology. Warts / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11174372.001).
  • [ISSN] 0190-9622
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / KO8 AR02030; United States / NIAMS NIH HHS / AR / P30 AR 42687; United States / NIAMS NIH HHS / AR / R03AR44947
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.11.24 / Mitogen-Activated Protein Kinases
  •  go-up   go-down


12. Laffosse JM, Accadbled F, Abid A, Kany J, Darodes P, Sales De Gauzy J: [Reconstruction of long bone defects with a vascularized fibular graft after tumor resection in children and adolescents: thirteen cases with 50-month follow-up]. Rev Chir Orthop Reparatrice Appar Mot; 2007 Oct;93(6):555-63
MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Reconstruction of long bone defects with a vascularized fibular graft after tumor resection in children and adolescents: thirteen cases with 50-month follow-up].
  • [Transliterated title] Reconstruction osseuse des os longs après exérèse carcinologique par l'utilisation de greffons fibulaires vascularisés chez l'enfant et l'adolescent.
  • PURPOSE OF THE STUDY: The vascularized fibular graft is a widely used technique for the reconstruction of long bone defects after tumor resection.
  • Complications are not uncommon despite the presence of a good vascular supply.
  • We report our experience with long bone reconstructions in children and adolescents after resection of primary malignant bone tumors.
  • Preoperatively, the pathological diagnosis was Ewing tumor (n=7), osteogenic sarcoma (n=5), neuroepithelioma (n=1).
  • All patients except one were given chemotherapy preoperatively and postoperatively and four received adjuvant radiotherapy.
  • Tumor resection created a gap (n=8) or involved resection-arthrodesis (n=5, three knees, one ankle, one elbow).
  • Eleven of the twelve patients who underwent tumor resection involving the lower limb were able to walk with full weight bearing at 13.9 months (range 841 months), half of them without any supportive device.
  • Among the fibular grafts which healed, primary healing of the distal end was noted in all cases, but not for the proximal end.
  • Complications were: skin necrosis (n=2), nonunion (n=4, three aseptic and one septic), disassembly (n=3 with two transplant fractures), and spontaneous fracture which healed (n=5, all but one treated orthopedically).
  • Healing was always achieved for the distal focus but not for the proximal focus which receives its blood supply from a branch of the anterior tibial artery which is not harvested.
  • [MeSH-minor] Adolescent. Arthrodesis / methods. Cause of Death. Chemotherapy, Adjuvant. Child. Child, Preschool. Follow-Up Studies. Fractures, Bone / etiology. Fractures, Spontaneous / etiology. Humans. Knee Joint / surgery. Lung Neoplasms / secondary. Neuroectodermal Tumors, Primitive, Peripheral / surgery. Osteosarcoma / surgery. Postoperative Complications. Radiotherapy, Adjuvant. Retrospective Studies. Sarcoma, Ewing / surgery. Treatment Outcome. Walking / physiology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Grafts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18065864.001).
  • [ISSN] 0035-1040
  • [Journal-full-title] Revue de chirurgie orthopédique et réparatrice de l'appareil moteur
  • [ISO-abbreviation] Rev Chir Orthop Reparatrice Appar Mot
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


13. Gambassi G, Semeraro R, Suma V, Sebastio A, Incalzi RA: Aggressive behavior of classical Kaposi's sarcoma and coexistence with angiosarcoma. J Gerontol A Biol Sci Med Sci; 2005 Apr;60(4):520-3
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histology allowed a diagnosis of the classical form of Kaposi's sarcoma; the serology test result for HIV was negative, whereas the associated human herpes virus type 8 was detected by polymerase chain reaction on the skin sample.
  • Over the subsequent 6 months, skin lesions become vegetative and partially necrotic, and extended to the hands and eyelids.
  • Chemotherapy with vinblastine appeared to stabilize the cutaneous disease, but the patient developed a massive gastrointestinal hemorrhage secondary to dissemination to the stomach.
  • This case illustrates that, even in its classical form, Kaposi's sarcoma may be a malignant, rapidly progressing tumor.
  • LEARNING POINTS: a) The extent and rate of spread of initial skin lesions should be considered to be early signs of aggressive dissemination, even in the absence of other variables (i.e., histological pattern, human herpes virus type 8 positive mononuclear cells) associated with progression of the disease.
  • c) When classical Kaposi's sarcoma displays aggressive behavior a second, primary malignant tumor arising from the vascular tissue should be investigated.
  • TAKE-HOME MESSAGE: Even in its classical form, Kaposi's sarcoma may be a malignant, rapidly progressing tumor with visceral involvement; also, a second malignancy may occur in nearly one patient of four.
  • Because localized skin lesions can regress completely with radiotherapy, watchful waiting is probably inappropriate in most cases.
  • [MeSH-major] Foot Diseases / pathology. Hemangiosarcoma / pathology. Neoplasms, Multiple Primary / pathology. Palatal Neoplasms / pathology. Sarcoma, Kaposi / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Fatal Outcome. Follow-Up Studies. Humans. Male. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Foot Injuries and Disorders.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15933395.001).
  • [ISSN] 1079-5006
  • [Journal-full-title] The journals of gerontology. Series A, Biological sciences and medical sciences
  • [ISO-abbreviation] J. Gerontol. A Biol. Sci. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Ravindranath MH, Muthugounder S, Presser N, Viswanathan S: Anticancer therapeutic potential of soy isoflavone, genistein. Adv Exp Med Biol; 2004;546:121-65
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anticancer therapeutic potential of soy isoflavone, genistein.
  • A significant correlation between the serum/plasma level of genistein and the incidence of gender-based cancers in Asian, European and American populations suggests that genistein may reduce the risk of tumor formation.
  • By blocking the activities of PTK, topoisomerase II and matrix metalloprotein (MMP9) and by down-regulating the expression of about 11 genes, including that of vascular endothelial growth factor (VEGF), genistein can arrest cell growth and proliferation, cell cycle at G2/M, invasion and angiogenesis.
  • Genistein acts synergistically with drugs such as tamoxifen, cisplatin, 1,3-bis 2-chloroethyl-1-nitrosourea (BCNU), dexamethasone, daunorubicin and tiazofurin, and with bioflavonoid food supplements such as quercetin, green-tea catechins and black-tea thearubigins.
  • Because it increases melanin production and tyrosinase activity, genistein can protect melanocytes of the skin of Caucasians from UV-B radiation-induced melanoma.
  • Although genistein has many potentially therapeutic actions against cancer, its biphasic bioactivity (inhibitory at high concentrations and activating at low concentrations) requires caution in determining therapeutic doses of genistein alone or in combination with chemotherapy, radiation therapy, and/or immunotherapies.
  • Of the more than 4500 genistein studies in peer-reviewed primary publications, almost one fifth pertain to its antitumor capabilities and more than 400 describe its mechanism of action in normal and malignant human and animal cells, animal models, in vitro experiments, or phase I/II clinical trials.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Genistein / therapeutic use. Neoplasms / drug therapy. Phytotherapy
  • [MeSH-minor] Animals. Cell Cycle / drug effects. Cell Division / drug effects. Female. Humans. Male. Soybeans

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GENISTEIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15584372.001).
  • [ISSN] 0065-2598
  • [Journal-full-title] Advances in experimental medicine and biology
  • [ISO-abbreviation] Adv. Exp. Med. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; DH2M523P0H / Genistein
  • [Number-of-references] 254
  •  go-up   go-down


15. Bong AB, Bonnekoh B, Schön MP, Gollnick H: Treatment of scalp angiosarcoma by controlled perfusion of A. carotis externa with pegylated liposomal doxorubicin and intralesional application of pegylated interferon alfa. J Am Acad Dermatol; 2005 Feb;52(2 Suppl 1):20-3
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of scalp angiosarcoma by controlled perfusion of A. carotis externa with pegylated liposomal doxorubicin and intralesional application of pegylated interferon alfa.
  • BACKGROUND: Angiosarcoma of the scalp is a rare but highly aggressive malignant tumor that differentiates toward vascular endothelial cells and shows a tendency for diffuse, often clinically occult spread.
  • OBSERVATIONS: A 65-year-old Caucasian man presented with multiple erythematous skin lesions at the right scalp hemisphere and a prominent forehead edema that had developed during a period of 2 months.
  • The clinical diagnosis of angiosarcoma was confirmed by histopathology.
  • Because of the advanced local progression of the tumor and the unilateral localization on the right side of the scalp, we initiated an intra-arterial chemotherapy using pegylated liposomal doxorubicin (Caelyx) (8 mg/cycle every 4 weeks by an A. carotis externa port system).
  • After 2 months, the tumor showed a marked regression; after 4 months, only one nodule located at the margins of the area perfused by the A. carotis externa persisted but regressed after focal irradiation.
  • At 30 months after diagnosis, the patient shows no recurrence of tumor growth.
  • CONCLUSIONS: In combination with intralesional interferon alfa, intra-arterial doxorubicin may be a promising innovative therapeutic option for localized scalp angiosarcoma, a hitherto poorly manageable and aggressive malignant tumor.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Head and Neck Neoplasms / drug therapy. Hemangiosarcoma / drug therapy. Scalp. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15692506.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Liposomes; 0 / Recombinant Proteins; 0 / peginterferon alfa-2b; 30IQX730WE / Polyethylene Glycols; 80168379AG / Doxorubicin; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


16. Tamura T, Minami H, Yamada Y, Yamamoto N, Shimoyama T, Murakami H, Horiike A, Fujisaka Y, Shinkai T, Tahara M, Kawada K, Ebi H, Sasaki Y, Jiang H, Saijo N: A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. J Thorac Oncol; 2006 Nov;1(9):1002-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors.
  • INTRODUCTION: ZD6474 (vandetanib) is an orally available inhibitor of vascular endothelial growth factor receptor, epidermal growth factor receptor, and RET receptor tyrosine kinase activity.
  • This study assessed the safety and tolerability of escalating doses of ZD6474 in Japanese patients with solid, malignant tumors.
  • METHODS: Adult patients with solid tumors refractory to standard therapy received a once-daily oral dose of ZD6474 (100-400 mg) in 28-day cycles, until disease progression or unacceptable toxicity was observed.
  • Dose-limiting toxicities at the completion of cycle 2 were hypertension (n = 3), diarrhea (n = 1), headache (n = 1), toxic skin eruption (n = 1), and alanine aminotransferase increase (n = 1).
  • Objective tumor response was observed in four of nine patients with non-small cell lung cancer (NSCLC) at doses of either 200 or 300 mg.
  • The objective response observed in some NSCLC patients is encouraging for further studies in this tumor type.
  • [MeSH-major] Neoplasm Invasiveness / pathology. Piperidines / administration & dosage. Piperidines / pharmacokinetics. Quinazolines / administration & dosage. Quinazolines / pharmacokinetics. Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors. Thoracic Neoplasms / drug therapy. Thoracic Neoplasms / pathology
  • [MeSH-minor] Administration, Oral. Adult. Aged. Disease-Free Survival. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Japan. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Risk Assessment. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17409986.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine; 0 / Piperidines; 0 / Quinazolines; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  •  go-up   go-down


17. Velazquez EF, Barreto JE, Rodriguez I, Piris A, Cubilla AL: Limitations in the interpretation of biopsies in patients with penile squamous cell carcinoma. Int J Surg Pathol; 2004 Apr;12(2):139-46
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Surgeons often perform small or superficial penile biopsies that are difficult to classify definitely with regard to a benign or malignant nature, and if malignant, cannot always be accurately subclassified.
  • Staging and therapeutic decisions rely on the identification, in these materials, of pathologic parameters related to prognosis.
  • The evaluated parameters were as follows: cancer diagnosis, histologic type, tumor grade, depth of invasion (anatomical levels), and vascular invasion.
  • Levels of invasion were lamina propria, corpus spongiosum, and corpus cavernosum in the glans; and lamina propria, dartos, and skin in the foreskin.
  • In 2 patients with well-differentiated tumors a diagnosis of cancer could not be established in biopsy material.
  • In 17 cases (30%) there was a biopsy-penectomy discordance of histologic types, especially of verruciform and mixed carcinomas.
  • Vascular invasion was identified in biopsies in only 1 of 8 patients.
  • In summary, biopsies were useful for cancer diagnosis except in 2 differentiated variants of penile squamous cell carcinoma.
  • Data from biopsies may be insufficient to make a decision whether to perform a groin dissection, or for prognostic evaluation in those patients in whom other treatment modalities (such as radiotherapy or chemotherapy) are being considered.
  • [MeSH-minor] Biopsy. Humans. Male. Neoplasm Invasiveness / pathology. Reproducibility of Results

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15173919.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Safwat A, Aggerholm N, Roitt I, Overgaard J, Hokland M: Tumour burden and interleukin-2 dose affect the interaction between low-dose total body irradiation and interleukin 2. Eur J Cancer; 2004 Jun;40(9):1412-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumour burden and interleukin-2 dose affect the interaction between low-dose total body irradiation and interleukin 2.
  • Low-dose total body irradiation (LTBI) has a synergistic immune-mediated antitumour effect when used in combination with interleukin 2 (IL-2) in a murine metastatic malignant melanoma model.
  • To optimise the use of this combination treatment this study was performed to test the effect of tumour burden and dose of both LTBI and IL-2 on the therapeutic potential of this treatment strategy.
  • Ten-week-old female C57BL/6 mice were inoculated intravenously (day 0) with 1 million B16F1 malignant melanoma cells.
  • Groups of mice received no treatment, a single fraction of LTBI alone, IL-2 treatment alone, or a combination of LTBI and IL-2.
  • LTBI was given on day +10 and IL-2 treatment started on day +11.
  • The lungs were removed and analysed for tumour burden.
  • LTBI (in the two tested doses) showed no independent therapeutic effects.
  • An IL-2 dose of 300,000 Cetus units (CU) that was effective and showed synergism with LTBI when mice were treated on day +7 failed to show a therapeutic effect when mice were treated on day +10, at which time the initial tumour burden had doubled.
  • Combining high-dose IL-2 with LTBI led to a further significant reduction in tumour burden.
  • Moreover, this combination was associated with a less severe vascular leakage syndrome compared to IL-2 alone.
  • IL-2 and combination treatment was associated with an increase in the number of tumour-infiltrating immune cells, but only the number of tumour-infiltrating natural killer cells reflected therapeutic efficacy.
  • It was concluded that tumour burden at the time of treatment and IL-2 dose are two crucial factors affecting the synergism between LTBI and IL-2.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Interleukin-2 / therapeutic use. Melanoma, Experimental / drug therapy. Melanoma, Experimental / radiotherapy. Skin Neoplasms / drug therapy. Skin Neoplasms / radiotherapy. Whole-Body Irradiation
  • [MeSH-minor] Animals. Combined Modality Therapy. Drug Administration Schedule. Female. Lymphocytes, Tumor-Infiltrating / immunology. Mice. Mice, Inbred C57BL

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15177501.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interleukin-2
  •  go-up   go-down


19. Zmonarski SC, Boratyńska M, Puziewicz-Zmonarska A, Kazimierczak K, Klinger M: Kaposi's sarcoma in renal transplant recipients. Ann Transplant; 2005;10(2):59-65
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kaposi's sarcoma (KS) is a spindle-shaped vascular cell tumor that occurs in the skin, lymphoid, respiratory and gastrointestinal tissues.
  • It may resemble aggressive malignant neoplasm in HIV-related or in post-transplant types but classic form may behave as benign, potentially controllable and reversible hyperplasia.
  • KS occurrence is associated with: type and dose of immunosuppression, chronic stimulation by foreign allograft antigens, viral infections (Herpes virus 8), anti rejection and induction therapy, etc.
  • Histological picture shows networks of spindle shaped cells and vascular spaces surrounded by an endothelial cell layer.
  • There is no uniform schema of KS treatment in renal transplant recipients.
  • After conversion to MMF regression of KS was observed, although low therapeutic MMF doses seem to be appropriate.
  • Sirolimus seems to inhibit the growth of established vascularized tumors and this effect is best realized with relatively low immunosuppressive doses of drug.

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16218035.001).
  • [ISSN] 1425-9524
  • [Journal-full-title] Annals of transplantation
  • [ISO-abbreviation] Ann. Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 25
  •  go-up   go-down


20. Schön MP, Schön M: Immune modulation and apoptosis induction: two sides of the antitumoral activity of imiquimod. Apoptosis; 2004 May;9(3):291-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, there is recent evidence that imiquimod is also efficacious against other tumors such as cutaneous metastases of malignant melanoma or vascular tumors.
  • The net result of this proinflammatory activity is a profound tumor-directed cellular immune response.
  • However, recent experimental and clinical data indicate that imiquimod also possesses considerable direct pro-apoptotic activity against tumor cells both in vitro and in vivo.
  • Bypassing molecular mechanisms of apoptosis deficiency by a topical compound may be of great utility for treating certain cutaneous tumors.
  • [MeSH-major] Adjuvants, Immunologic / pharmacology. Aminoquinolines / pharmacology. Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Neoplasms / drug therapy
  • [MeSH-minor] Administration, Topical. Animals. Carcinoma, Basal Cell / drug therapy. Caspases / metabolism. Cytochrome c Group / metabolism. Enzyme Activation. Humans. Melanoma / drug therapy. Mitochondria / enzymology. Models, Biological. Ointments. Proto-Oncogene Proteins c-bcl-2 / metabolism. Skin Neoplasms / drug therapy. Vascular Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15258460.001).
  • [ISSN] 1360-8185
  • [Journal-full-title] Apoptosis : an international journal on programmed cell death
  • [ISO-abbreviation] Apoptosis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Cytochrome c Group; 0 / Ointments; 0 / Proto-Oncogene Proteins c-bcl-2; 99011-02-6 / imiquimod; EC 3.4.22.- / Caspases
  • [Number-of-references] 65
  •  go-up   go-down


21. Aggarwal BB, Sundaram C, Malani N, Ichikawa H: Curcumin: the Indian solid gold. Adv Exp Med Biol; 2007;595:1-75
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since the time of Ayurveda (1900 Bc) numerous therapeutic activities have been assigned to turmeric for a wide variety of diseases and conditions, including those of the skin, pulmonary, and gastrointestinal systems, aches, pains, wounds, sprains, and liver disorders.
  • Curcumin has been shown to exhibit antioxidant, anti-inflammatory, antiviral, antibacterial, antifungal, and anticancer activities and thus has a potential against various malignant diseases, diabetes, allergies, arthritis, Alzheimer's disease, and other chronic illnesses.
  • Curcumin exhibits activities similar to recently discovered tumor necrosis factor blockers (e.g., HUMIRA, REMICADE, and ENBREL), a vascular endothelial cell growth factor blocker (e.g., AVASTIN), human epidermal growth factor receptor blockers (e.g., ERBITUX, ERLOTINIB, and GEFTINIB), and a HER2 blocker (e.g., HERCEPTIN).
  • Considering the recent scientific bandwagon that multitargeted therapy is better than monotargeted therapy for most diseases, curcumin can be considered an ideal "Spice for Life".
  • [MeSH-major] Curcumin / therapeutic use. Medicine, Ayurvedic. Phytotherapy. Plants, Medicinal
  • [MeSH-minor] Animals. Anti-Bacterial Agents / chemistry. Anti-Bacterial Agents / pharmacology. Anti-Bacterial Agents / therapeutic use. Anti-Inflammatory Agents, Non-Steroidal / chemistry. Anti-Inflammatory Agents, Non-Steroidal / pharmacology. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Antifungal Agents / chemistry. Antifungal Agents / pharmacology. Antifungal Agents / therapeutic use. Antineoplastic Agents, Phytogenic / chemistry. Antineoplastic Agents, Phytogenic / pharmacology. Antineoplastic Agents, Phytogenic / therapeutic use. Antioxidants / chemistry. Antioxidants / pharmacology. Antioxidants / therapeutic use. Antiviral Agents / chemistry. Antiviral Agents / pharmacology. Antiviral Agents / therapeutic use. Arthritis, Rheumatoid / drug therapy. Curcuma / chemistry. Humans. India. Models, Biological. Molecular Structure. Neoplasms / drug therapy. Spices. Structure-Activity Relationship

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CURCUMIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17569205.001).
  • [ISSN] 0065-2598
  • [Journal-full-title] Advances in experimental medicine and biology
  • [ISO-abbreviation] Adv. Exp. Med. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antifungal Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Antioxidants; 0 / Antiviral Agents; IT942ZTH98 / Curcumin
  • [Number-of-references] 974
  •  go-up   go-down


22. Karrer S, Szeimies RM, Hohenleutner U, Landthaler M: Role of lasers and photodynamic therapy in the treatment of cutaneous malignancy. Am J Clin Dermatol; 2001;2(4):229-37
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of lasers and photodynamic therapy in the treatment of cutaneous malignancy.
  • Tumor therapy is not a common indication for the use of lasers, as it is in the treatment of benign vascular skin lesions, since many alternative treatment modalities exist.
  • However, certain patients may benefit from laser therapy of premalignant and malignant skin tumors.
  • Skin tumors can be treated by laser excision, laser coagulation, laser vaporization, or photodynamic therapy (PDT).
  • PDT is a therapeutic approach based on the photosensitization of the target tissue by topical or systemic photosensitizers and subsequent irradiation with light from a laser or a lamp inducing cell death via generation of reactive oxygen species.
  • Laser therapy and PDT have shown good results in the curative treatment of actinic keratoses, superficial basal cell carcinoma, Bowen's disease and cheilitis actinica.
  • However, they are not recommended for primary malignant melanoma and invasive squamous cell carcinoma.
  • In some patients, lasers and PDT might also be used effectively for the palliative treatment of cutaneous metastases.
  • However, when treating invasive tumors with curative intention, one has to bear in mind the lack of histologic control and the limited depth of tissue penetration of most laser and PDT therapies.
  • [MeSH-major] Laser Therapy. Photochemotherapy. Precancerous Conditions / therapy. Skin Neoplasms / therapy
  • [MeSH-minor] Aged. Aminolevulinic Acid / therapeutic use. Bowen's Disease / drug therapy. Bowen's Disease / surgery. Carcinoma, Basal Cell / drug therapy. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / surgery. Clinical Trials as Topic. Female. Follow-Up Studies. Humans. Hutchinson's Melanotic Freckle / drug therapy. Hutchinson's Melanotic Freckle / surgery. Laser Coagulation. Leukoplakia, Oral / drug therapy. Leukoplakia, Oral / surgery. Male. Melanoma / drug therapy. Melanoma / surgery. Middle Aged. Palliative Care. Photosensitizing Agents / therapeutic use. Sarcoma, Kaposi / drug therapy. Sarcoma, Kaposi / surgery. Time Factors

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11705250.001).
  • [ISSN] 1175-0561
  • [Journal-full-title] American journal of clinical dermatology
  • [ISO-abbreviation] Am J Clin Dermatol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  • [Number-of-references] 59
  •  go-up   go-down


23. Thamm DH, Huelsmeyer MK, Mitzey AM, Qurollo B, Rose BJ, Kurzman ID: RT-PCR-based tyrosine kinase display profiling of canine melanoma: IGF-1 receptor as a potential therapeutic target. Melanoma Res; 2010 Feb;20(1):35-42
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RT-PCR-based tyrosine kinase display profiling of canine melanoma: IGF-1 receptor as a potential therapeutic target.
  • Canine malignant melanoma (CMM) resembles human malignant melanoma in terms of metastatic behavior, refractoriness to standard therapy, and tumor antigen expression but it is largely unknown how CMM resembles human melanoma with regard to molecular pathogenesis and cellular signaling.
  • IGF-1 stimulated cell proliferation and vascular endothelial growth factor production in 17CM98, and addition of the IGF-1R inhibitor ADW742 abrogated IGF-1-induced phenotypic changes.
  • Expression of IGF-1R mRNA was detected in five of five additional CMM cell cultures, and IGF-1R protein was detected in five of six primary tumors evaluated, suggesting that IGF-1R expression may be common in CMM and may provide a novel target for future therapy.
  • [MeSH-major] Dog Diseases / enzymology. Melanoma / enzymology. Melanoma / veterinary. Protein-Tyrosine Kinases / biosynthesis. Receptor, IGF Type 1 / antagonists & inhibitors. Reverse Transcriptase Polymerase Chain Reaction / veterinary. Skin Neoplasms / veterinary
  • [MeSH-minor] Animals. Cell Line, Tumor. Dogs. Humans. Protein Kinase Inhibitors / pharmacology. Pyrimidines / pharmacology. Pyrroles / pharmacology. Signal Transduction / drug effects

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19949352.001).
  • [ISSN] 1473-5636
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ADW 742; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Pyrroles; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, IGF Type 1
  •  go-up   go-down


24. Moarbess G, El-Hajj H, Kfoury Y, El-Sabban ME, Lepelletier Y, Hermine O, Deleuze-Masquéfa C, Bonnet PA, Bazarbachi A: EAPB0203, a member of the imidazoquinoxaline family, inhibits growth and induces caspase-dependent apoptosis in T-cell lymphomas and HTLV-I-associated adult T-cell leukemia/lymphoma. Blood; 2008 Apr 1;111(7):3770-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Imiquimod is an immune response modifier currently used as a topical treatment of genital warts, basal cell carcinoma, cutaneous metastasis of malignant melanoma, and vascular tumors.
  • We developed more efficient killers from the same family of compounds that can induce apoptosis without the prominent pro-inflammatory response associated with imiquimod.
  • Using potentially achievable concentrations of EAPB0203, we demonstrate inhibition of cell proliferation, G2/M cell- cycle arrest, and induction of apoptosis in HTLV-I-transformed and HTLV-I-negative malignant T cells and fresh ATL cells, whereas normal resting or activated T lymphocytes were resistant.
  • EAPB0203 treatment significantly down-regulated the antiapoptotic proteins c-IAP-1 and Bcl-XL and resulted in a significant loss of mitochondrial membrane potential, cytoplasmic release of cytochrome c, and caspase-dependent apoptosis.
  • Moreover, in HTLV-I-transformed cells only, EAPB0203 treatment stabilized p21 and p53 proteins but had no effect on NF-kappaB activation.
  • These results support a potential therapeutic role for EAPB0203 in ATL and HTLV-I-negative T-cell lymphomas, either as a systemic or topical therapy for skin lesions.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Caspases / metabolism. Cell Division / drug effects. G2 Phase / drug effects. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Lymphoma, T-Cell / drug therapy. Quinoxalines / pharmacology. Skin Neoplasms / drug therapy
  • [MeSH-minor] Aminoquinolines / adverse effects. Aminoquinolines / pharmacology. Aminoquinolines / therapeutic use. Cytochromes c / metabolism. Human T-lymphotropic virus 1 / metabolism. Humans. Inflammation / chemically induced. Inflammation / metabolism. Inflammation / pathology. Inhibitor of Apoptosis Proteins / antagonists & inhibitors. Inhibitor of Apoptosis Proteins / metabolism. Jurkat Cells. Lymphocyte Activation / drug effects. Membrane Potential, Mitochondrial / drug effects. NF-kappa B / metabolism. Tumor Suppressor Protein p53 / metabolism. bcl-X Protein / antagonists & inhibitors. bcl-X Protein / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Imiquimod .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18218850.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / BCL2L1 protein, human; 0 / EAPB0203; 0 / Inhibitor of Apoptosis Proteins; 0 / NF-kappa B; 0 / Quinoxalines; 0 / Tumor Suppressor Protein p53; 0 / bcl-X Protein; 9007-43-6 / Cytochromes c; 99011-02-6 / imiquimod; EC 3.4.22.- / Caspases
  •  go-up   go-down






Advertisement